Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Anagnostics Enters Sales Cooperation with Analis S.A.

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
Company enters cooperation for Belgium and Luxembourg.

The Belgian company is specialized on clinical diagnostics and distributes Anagnostics’ innovative laboratory in the areas of drugs of abuse screening, personalized medicine (oncology) and sepsis diagnostics.

Since this summer Analis S.A. from Suarlée (near Namur) offers Anagnostics’ diagnostic products for drugs of abuse screening and personalized medicine.

In the coming months the sales portfolio will be enlarged by tests supporting the diagnosis and therapy of sepsis.

Analis and Anagnostics aim to serve hospitals in the Belux countries by offering truly innovative products and first class service.

“Analis is specialized on clinical diagnostics for a broad and loyal customer base and emphasizes first class support and advice of customers. Therewith Analis is the ideal partner for the distribution of our laboratory tests in Belgium and Luxembourg”, comments Christoph Reschreiter, CEO of Anagnostics Bioanalysis GmbH.

Guy Stukkens, CEO of Analis S.A. is looking forward to the sales cooperation: “We clearly see the trend towards more specific as well as more targeted and faster diagnostics, which is offered by multiplexed diagnostics. Anagnostics reacted on this need perfectly well. With the hyborg device and the test portfolio Anagnostics offers good market opportunities. The fast and efficient testing of drugs of abuse consumption ensures access to therapy institutions. The simple and highly sensitive tests in personalized medicine are particularly advantageous for small and medium sized pathologies, because cost efficiency is ensured even with low sample numbers.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vela Laboratories and Anagnostics Enter Strategic Partnership
Partnership to offer hybcell technology to biotech and pharma customers under GMP conditions.
Thursday, May 24, 2012
Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!